Avadel Pharmaceuticals (AVDL) Projected to Post Quarterly Earnings on Monday

Avadel Pharmaceuticals (NASDAQ:AVDL) is expected to be issuing its quarterly earnings data before the market opens on Monday, March 3rd. Analysts expect the company to announce earnings of ($0.03) per share for the quarter.

Avadel Pharmaceuticals Trading Down 0.7 %

Avadel Pharmaceuticals stock opened at $8.41 on Monday. Avadel Pharmaceuticals has a 12 month low of $7.39 and a 12 month high of $19.09. The stock’s 50 day moving average is $9.08 and its 200-day moving average is $11.87. The company has a market capitalization of $810.40 million, a price-to-earnings ratio of -10.65 and a beta of 1.28.

Insiders Place Their Bets

In other Avadel Pharmaceuticals news, Director Peter J. Thornton acquired 10,000 shares of Avadel Pharmaceuticals stock in a transaction that occurred on Monday, January 13th. The shares were acquired at an average cost of $8.04 per share, with a total value of $80,400.00. Following the completion of the purchase, the director now directly owns 104,055 shares of the company’s stock, valued at $836,602.20. This represents a 10.63 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Linda Palczuk purchased 3,000 shares of Avadel Pharmaceuticals stock in a transaction dated Friday, December 6th. The stock was bought at an average price of $10.19 per share, for a total transaction of $30,570.00. Following the completion of the purchase, the director now owns 66,400 shares in the company, valued at $676,616. This represents a 4.73 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 55,579 shares of company stock worth $526,363 over the last ninety days. Corporate insiders own 4.80% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on AVDL. Deutsche Bank Aktiengesellschaft began coverage on Avadel Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $12.00 price objective on the stock. Oppenheimer upped their price target on shares of Avadel Pharmaceuticals from $29.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Piper Sandler decreased their price target on shares of Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. UBS Group decreased their target price on shares of Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, January 13th. Finally, HC Wainwright restated a “buy” rating and set a $21.00 target price (down previously from $25.00) on shares of Avadel Pharmaceuticals in a research report on Friday, January 10th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $19.88.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.